Welcome to PhaLP: the database of Phage Lytic Proteins.
Phage lytic proteins (PhaLPs) are currently the most advanced alternative antibacterials under clinical investigation. These enzymes originate from bacteriophages and rapidly degrade bacterial peptidoglycan, resulting in immediate cell death. They offer a necessary response to the alarming threat of antibiotic resistance on global health care systems. One of the most important features of PhaLPs is that they can be considered as a novel class of antibiotics, coined enzybiotics, with the potential of targeting any specific bacterial pathogen. A growing community of companies and researchers is therefore investigating their applications and engineering their properties to kill a broad diversity of bacteria. Considering the high attrition rates during clinical evaluation, it is essential to get a higher number of candidates in the preclinical pipeline for a guaranteed translation of PhaLPs into diverse new therapies. To be successful, it is crucial to make well-considered selections of PhaLPs during early research stages.
The PhaLP database provides an extensive, high-quality and up-to-date collection of data that is highly searchable by researchers in and outside the field. It serves as a portal to interact with the current diversity available in biological databases. Next to basic sequence data, the PhaLP database provides information on the protein sequence, coding domain sequence (CDS), phage, its host(s), conserved domains, enzymatic activity, gene ontologies, 3D structures, experimental evidence, etc.
To interact with the PhaLP database, two user interfaces are provided:
PhaLPs are essential for the successful completion of the lytic life cycle of bacteriophages (panel A). There are two types of natural PhaLPs: virion-associated lysins (VALs) and endolysins. They are required in two stages (stages 1 and 6) of the life cycle. Initially, phages need to cross the bacterial cell wall and thereby overcome the major structural component of the cell wall: peptidoglycan. In the infection stage (stage 1) the virion particle encounters a bacterial cell and, after binding, needs to inject its genomic material into the cell. To achieve this, so called VALs make a small pore in the peptidoglycan layer allowing for the phage genome to cross (stage 2; panel B, left). After genome replication (stage 3), virion production (stage 4) and assembly (stage 5), the phage progeny is ready to be set free. Meanwhile, endolysins have been accumulating in the cytosol and holins in the cytoplasmic membrane. Once the holin concentration has reached a certain threshold, they will multimerize and form pores, allowing the endolysins to enter the periplasmic space (panel B, right). Here, the endolysins will degrade the peptidoglycan and compromise the structural integrity of the cell with lysis and cell death as a result (stage 6).